[go: up one dir, main page]

Thimmasetty et al., 2021 - Google Patents

Oral bioavailability enhancement of paliperidone by the use of cocrystalization and precipitation inhibition

Thimmasetty et al., 2021

Document ID
16190966570952417605
Author
Thimmasetty J
Ghosh T
Nayak N
Raheem A
Publication year
Publication venue
Journal of Pharmaceutical Innovation

External Links

Snippet

Purpose The aim of the study was to improve bioavailability of paliperidone, a class II drug, via cocrystallization with a peep to the effect of HPMC as a precipitation inhibitor (PPI). An attempt was made to prepare paliperidone cocrystals with benzamide, boric acid …
Continue reading at link.springer.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring

Similar Documents

Publication Publication Date Title
Thimmasetty et al. Oral bioavailability enhancement of paliperidone by the use of cocrystalization and precipitation inhibition
Shayanfar et al. Drug–drug coamorphous systems: characterization and physicochemical properties of coamorphous atorvastatin with carvedilol and glibenclamide
McNamara et al. Use of a glutaric acid cocrystal to improve oral bioavailability of a low solubility API
Dengale et al. Preparation and characterization of co-amorphous Ritonavir–Indomethacin systems by solvent evaporation technique: Improved dissolution behavior and physical stability without evidence of intermolecular interactions
Ober et al. Formation of itraconazole–succinic acid cocrystals by gas antisolvent cocrystallization
Fung et al. Physical stability and dissolution behavior of ketoconazole–organic acid coamorphous systems
Basavoju et al. Indomethacin–saccharin cocrystal: design, synthesis and preliminary pharmaceutical characterization
Müllers et al. Simultaneous Formation and Micronization of Pharmaceutical Cocrystals by Rapid Expansion of Supercritical Solutions (RESS) Müllers, Paisana and Wahl
Patole et al. Co-crystallization-a technique for solubility enhancement
Hyun et al. Preparation, characterization, and evaluation of celecoxib eutectic mixtures with adipic acid/saccharin for improvement of wettability and dissolution rate
Nikam et al. Pharmaceutical cocrystals of nebivolol hydrochloride with enhanced solubility
Huang et al. Combination of co-crystal and nanocrystal techniques to improve the solubility and dissolution rate of poorly soluble drugs: Huang, Staufenbiel and Bodmeier
Tao et al. Phenazopyridine cocrystal and salts that exhibit enhanced solubility and stability
Shayanfar et al. Coamorphous atorvastatin calcium to improve its physicochemical and pharmacokinetic properties
Tipduangta et al. A new low melting-point polymorph of fenofibrate prepared via talc induced heterogeneous nucleation
Hiendrawan et al. Pharmaceutical salts of carvedilol: polymorphism and physicochemical properties
Zhang et al. New polymorphs of Huperzine A: preparation, structures, and physicochemical properties of anhydrous crystal forms
Vemuri et al. Rosuvastatin cocrystals: an attempt to modulate physicochemical parameters
Cho et al. Preparation and characterization of aripiprazole cocrystals with coformers of multihydroxybenzene compounds
Kara et al. In silico screening as a tool to prepare drug-drug cocrystals of ibrutinib-ketoconazole: a strategy to enhance their solubility profiles and oral bioavailability
Haneef et al. Implication of coformer structural diversity on cocrystallization outcomes of telmisartan with improved biopharmaceutical performance
Zheng et al. Structures of polymorphic agomelatine and its cocrystals with acetic acid and ethylene glycol
Shi et al. Improving the Solubility and Dissolution of Ibrutinib by preparing Solvates
Bolla et al. Pentamorphs of acedapsone
Mehta et al. Para-hydroxy benzoic acid coformer enable enhanced solubility, dissolution, and antifungal activity of ketoconazole cocrystals